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Abstract
Objective To investigate the diagnostic value of whole-body
magnetic resonance imaging (MRI) including diffusion-
weighted imaging with background signal suppression
(DWIBS) for preoperative assessment of non-small-cell
lung cancer (NSCLC) in comparison to 18F-fluorodeoxyglu-
cose 18FDG) positron emission tomography/computed to-
mography (PET/CT).
Methods Thirty-three patients with suspected NSCLC were
enrolled. Patients were examined before surgery with PET/
CT and whole-body MRI including T1-weighted turbo spin
echo (TSE), T2-weighted short tau inversion recovery
(STIR) and DWIBS sequences (b00/800). Histological or
cytological specimens were taken as standard of reference.
Results Whole-body MRI with DWIBS as well as PET/CT
provided diagnostic image quality in all cases. Sensitivity
for primary tumour detection: MRI 93%, PET/CT 98%. T-
staging accuracy: MRI 63%, PET/CT 56%. N-staging accu-
racy: MRI 66%, PET/CT 71%. UICC staging accuracy:
MRI 66%, PET/CT 74%. Sensitivity for metastatic involve-
ment of individual lymph node groups: MRI 44%, PET/CT
47%. Specificity for individual non-metastatic lymph node
groups: MRI 93%, PET/CT 96%. Assessment accuracy for
individual lymph node groups: MRI 85%, PET/CT 88%.
Observer agreement rate for UICC staging: MRI 74%, PET/
CT 90%.
Conclusion Whole-body MRI with DWIBS provides com-
parable results to PET/CT in staging of NSCLC, but shows
no superiority. Most relevant challenges for both techniques
are T-staging accuracy and sensitivity for metastatic lymph
node involvement.
Key Points
• Numerous radiological methods are available for the
crucial staging of lung cancer
• Whole-body DWIBS MRI provides comparable results to
PET/CT in NSCLC staging.
• No evident superiority of whole-body DWIBS over PET/
CT in NSCLC staging.
• Challenges for both techniques are T-staging and detection
of small metastases.
Keywords Non-small-cell lung carcinoma . Neoplasm
staging .Whole-body imaging . Diffusion magnetic
resonance imaging . Positron emission tomography
Introduction
Lung cancer is the leading cause of cancer-related death and
accounts for 14% of all new cases of cancer in the USA in
2011 [1]. Accurate staging is mandatory to select the most
appropriate therapy and to determine prognosis. Combined
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18F-fluorodeoxyglucose positron emission tomography and
computed tomography (PET/CT) is considered as the stan-
dard of reference for preoperative assessment of non-small-
cell lung cancer (NSCLC) [2, 3]. Despite its widespread use
and high degree of standardisation, the results provided by
PET/CT are still not totally satisfying. Limitations of PET/
CT are particularly limited spatial resolution [4] and low
specificity in distinguishing malignant lymphadenopathy
from inflammatory changes, resulting in a considerable
number of false-positive findings [5]. Moreover, PET/CT
is associated with a considerable radiation burden to patients
and medical personnel.
Magnetic resonance imaging (MRI) is currently the only
technique that enables non-invasive whole-body assessment
without ionising radiation. Another strength of MRI is its
capability to create high soft tissue contrast without external
contrast agents and with high spatial resolution. A novel
powerful source of contrast generation for whole-body MRI
became available in 2004 with the introduction of diffusion-
weighted imaging with background signal suppression
(DWIBS) [6]. The image contrast of DWIBS is based on
the diffusion properties of water molecules and reflects
tissue parameters like cellular density and tissue architecture
[7]. In the last few years, DWIBS has been investigated
successfully in many fields of oncology [8]. Also for
NSCLC, an increasing number of studies on DWI became
available [9–24]. Only a few studies have addressed valida-
tion DWI versus PET/CT as standard of reference. Among
the data that have been published up till now, four studies
focus on tumour detection and characterisation of lung
nodules [9–12], four studies on N-staging and character-
isation of mediastinal lymph nodes [11–14], and two studies
on M-staging [12, 15]. Only one study [11] provides data on
overall staging accuracy according to the Union for Interna-
tional Cancer Control (UICC) classification. To the best of
our knowledge, this is the first study presenting data on T-
staging accuracy of MRI with diffusion weighting.
The objective of this study is to assess the diagnostic
value of whole-body MRI with DWIBS in comparison to
PET/CT for comprehensive preoperative assessment of
NSCLC in a clinical setting. Data evaluation included pri-
mary tumour detection, T-staging, detection of individual
lymph node metastases, N-staging and UICC staging with
histopathology and cytology as the reference standards.
Materials and methods
Patients
Thirty-three patients (24 men, 9 women, mean age 63.7 years,
median age 66 years, age range 43–83 years) with suspected
NSCLC were prospectively enrolled. All patients underwent
PET/CTand were scheduled for surgery according to the PET/
CT findings. Whole-body MRI examinations were performed
before surgery. In one patient, surgery was cancelled due to
negative results in an additional transbronchial biopsy that
was done after the MRI exam. The histological subtypes of
pulmonary malignancies represented according to the WHO/
IASLC classification [25] were adenocarcinoma (16 cases),
squamous cell carcinoma (eight cases), adenosquamous car-
cinoma (one case), large cell carcinoma (two cases) and well
differentiated neuroendocrine tumour (one case). Two patients
were excluded from statistical evaluation as histology
revealed malignant lesions of non-pulmonary origin (one
lymphoma, one colon cancer metastasis). Three patients were
diagnosed as negative for lung cancer by histology or cytolo-
gy (one tuberculosis, one respiratory bronchiolitis-interstitial
lung disease [RB-ILD], one inconclusive). The mean time
interval between imaging and surgery was 34 (± 26) days
for PET/CT and 3 (± 2) days for MRI. Three patients received
surgical resection after neo-adjuvant radiation and/or chemo-
therapy. However, no therapy was performed between imag-
ing and surgery. All procedures were in accordance with the
ethical standards of the World Medical Association and writ-
ten informed consent was obtained from all patients. The
study was approved by the local ethics committee.
Imaging protocol
PET/CT examinations were performed on an integrated PET/
CT system with 16-slice CT (Discovery; GE Healthcare,
Chalfont St Giles, UK). 18F-FDG was administered in a
standard dose of 5 MBq per kg body weight (maximum dose
500 MBq) 60 min before imaging after a fasting period of a
minimum of 6 h. For PETacquisition, eight bed positions with
each 4-min data acquisition were obtained from skull to upper
thigh. All patients received unenhanced low-dose CT for
attenuation correction and anatomical reference (tube
voltage0120 kV, tube current0100 mA, collimation016×
3.75 mm, free breathing). In patients who had not previously
undergone a dedicated chest CT examination, additional con-
trast enhanced CT of the chest was performed (tube voltage0
120 kV, tube current0300 mA, collimation016×1.25 mm,
breath hold, 80 ml intravenous iodinated contrast medium).
MRI examinations were performed on a 1.5-Twhole-body
MRI (Magnetom Avanto or Magnetom Symphony, Siemens
Healthcare, Erlangen, Germany) using a dedicated 18-
channel coil array system (total imaging matrix [Tim], Sie-
mens Healthcare). The sequences employed were T1-
weighted turbo spin echo (TSE) (TR0682 ms, TE011 ms,
matrix size0320×240 pixels, slice thickness05 mm, field of
view (FoV)0500×375 mm2, acquisition time 7×1:01 min),
T2-weighted short tau inversion recovery (STIR) (TR0
9,930 ms, TE086 ms, TI0160 ms, matrix size0320×240
pixels, slice thickness05 mm, FoV0500×375 mm2,
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acquisition time 7×1:19 min), and DWIBS (single shot echo
planar imaging [ss-EPI], TR05,400 ms, TE058 ms, b00 and
800 s/mm2, STIR fat suppression with TI0180 ms, matrix
size0192×144 pixels, slice thickness05 mm, FoV0500×
375 mm2, four averages, acquisition time 7×1:43 min) in
transverse orientation, each covering the patients’ body in
seven acquisition steps from skull to upper thigh. Total ex-
amination time was 30 min. All data were acquired during
free breathing. No contrast agent was applied. Apparent dif-
fusion coefficients (ADCs) were calculated pixel-wise (linear
fit to logarithmical data) and displayed as ADC maps. Image
fusion of T1-weighted and high b-value DWI data was per-
formed three-dimensionally in a semiautomatic fashion and
rendered in transverse and coronal image stacks.
Image analysis
Initial assessment of the PET/CT examinations was done as
part of the routine work by a board-certified nuclear medicine
physician with more than 5 years’ experience in PET/CT
reading (Reader 1). Separate blinded study readings were
performed >4 weeks later in three cases where data from a
previous PET/CT examination had been used during the
initial reading procedures. Second reading of all PET/CT
examinations was done by a board-certified nuclear medicine
physician with more than 10 years’ experience in PET/CT
reading (Reader 2). Both low-dose and contrast enhanced CT
datasets were used for the PET/CT readings. MRI examina-
tions were read by a board-certified radiologist with more than
5 years’ experience inMRI reading (Reader 1) and in a second
reading procedure by a board-certified radiologist with more
than 10 years’ experience in MRI reading (Reader 2). All
datasets (T1-weighted, T2-weighted STIR and DWIBS) were
considered for diagnosis. All readers were blinded to the
results of the other imaging technique and histopathology
results. Previous images from investigations other than PET/
CT and MRI were available to all readers. Image reading was
done on commercially available workstations (Centricity RA
1000; GE Healthcare).
Image quality of MRI was assed on a four-point scale
(very good 0 dataset with no visible artefacts; good 0 slight
motion artefacts that do not affect diagnostic assessment;
fair 0 artefacts that tolerably affect diagnostic assessment;
unsatisfactory 0 non-diagnostic data). Evaluation was done
both for the entire study and separately for the three indi-
vidual sequences. Image quality of PET/CT was assessed
overall using the same scale as for the MRI examinations.
Staging was done for each technique according to the 7th
edition TNM and UICC classifications [26]. Both PET/CT
and MRI images were interpreted in a qualitative manner
considering both morphological and functional information.
Increased FDG-uptake and restricted diffusion were identi-
fied by visual comparison of the lesion’s signal to the FDG-
uptake of the liver parenchyma in PET and the background
signal in high b-value DWI, respectively. Quantitative val-
ues for standardised uptake value (SUV) and ADC were
calculated and used for interpretation of particular findings
if found appropriate by the readers. However, no general
cut-off values were applied for differentiating benign from
malignant lesions. For lymph node assessment, a short axis
diameter of >1 cm was regarded as a morphological criterion
for metastatic involvement.
Lymph node stations were divided into three groups for
individual assessment (Sn0stations according to the IASLC
lymph node map [27], i 0 ipsilateral, c 0 contralateral): (1)
N1-nodes: ipsilateral intrapulmonary, peribronchial and hilar
nodes (S10-14); (2) N2-nodes: subcarinal nodes (S7), ipsilateral
mediastinal and para-aortic nodes (S2-6i, 8-9i); (3) N3-nodes:
contralateral mediastinal and para-aortic nodes (S2-6c, 8-9c),
and supraclavicular nodes (S1). A group of lymph node sta-
tions was rated positive, if at least one lymph node from one
of the stations was considered to be metastatic.
Statistical analysis
Overall accuracy was calculated for primary tumour detec-
tion, T-staging, N-staging, group-wise assessment of lymph
nodes and UICC staging. Sensitivity, specificity, positive
predictive value (PPV) and negative predictive value
(NPV) were calculated for primary tumour detection and
group-wise assessment of lymph nodes. All measures were
calculated along with their corresponding exact binomial
95% confidence intervals. A retrospective size analysis
was performed based on the histology reports on those
lymph node groups that were rated false negative by at least
one of the four observers. Inter-observer agreement was
assessed by calculating percentages of actually observed
agreement without correction for effects of chance along
with the corresponding exact binomial 95% confidence
intervals. Statistical significance of the differences between
the staging results obtained by PET/CT and MRI was tested
using McNemar’s test. Image quality ratings were compared
by Wilcoxon signed-rank test. A P value of less than 0.05
was considered statistically significant.
Results
Whole-body MRI with DWIBS as well as PET/CT provided
diagnostic image quality in all cases. Overall image quality
for PET/CTwas rated very good in 14 cases (45%), and good
in the remaining 17 cases (55%), which was significantly
better (P00.01) than for MRI (very good, 7 [23%]; good, 20
[65%]; fair, 4 [13%]). Most important artefacts seen in MRI
were ghosting artefacts from cardiovascular pulsations that
affected morphological assessment of mediastinal structures.
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Assessment of individual MRI sequences revealed no signif-
icant differences (P>0.1) between DWI (very good, 6 [19%];
good, 21 [68%]; fair, 4 [13%]), T1-weighted TSE (very good,
7 [23%]; good, 18 [58%]; fair, 6 [19%]) and T2-weighted
STIR (very good, 8 [15%]; good, 15 [48%]; fair, 8 [15%]).
The results of MRI and PET/CT for the detection of
primary tumour lesions are displayed in Table 1. The indi-
vidual numbers represent average values from two readers.
Table 2 displays the T-staging results of the two techniques.
Overall T-staging accuracy was higher for MRI (63%) than
for PET/CT (56%). This difference, however, was not sta-
tistically significant (P00.6).
Table 3 displays the N-staging results for MRI and PET/
CT. N-staging accuracy was 66% for MRI and 71% for PET/
CT. The results of group-wise assessment of metastatic lymph
node involvement by MRI and PET/CTare shown in Table 4.
Amean number of nine lymph node groups in total were rated
false negative by each technique. In three cases, single me-
tastases with sizes between 4 mm and 7 mm (maximum
diameters measured by the pathologist on the surgical speci-
men) were missed by all four observers. In two cases, metas-
tases with sizes of 8 mm and 15 mm were missed by both
PET/CT readers, but were detected by one of theMRI readers.
In another two cases, metastases with sizes of 7 mm and
15 mm that were detected by one of the PET/CT readers were
missed by both observers with MRI. Metastatic involvement
of the remaining six lymph node groups was detected by at
least one observer from each technique.
UICC staging results are displayed in Table 5. Compar-
ison of methods by McNemar’s test revealed no statistically
significant difference between MRI and PET/CT for any of
the calculated measures. The P value obtained for compar-
ison of accuracy were 0.7 for primary tumour detection, 0.6
for T-staging, 0.65 for N-staging, 0.42 for assessment of
individual lymph node groups and 0.4 for UICC staging.
Figures 1 and 2 display two sample cases with discrepant
diagnoses for T- and N-stage between the two modalities. A
schematic overview on tumour detection and staging accu-
racies for both techniques is given in Fig. 3.
Observer agreement rates were 52% (34–70%) for T-
staging, 68% (52–84%) for N-staging and 74% (59–89%)
for UICC staging with MRI compared with 65% (48–82%),
68% (52–84%) and 90% (79–100%) with PET/CT. Inter-
observer agreement generally tended to be higher for PET/
CT than for MRI. However, differences were not statistically
significant (P00.22, 0.87 and 0.09).
Discussion
The objective of this study was to assess the diagnostic
value of whole-body MRI with DWIBS for comprehensive
Table 1 Detection of primary
NSCLC by MRI and FDG-PET/
CT (average values from two
readers). Values in parentheses
indicate 95% confidence
intervals
Primary tumour detection MRI PET/CT
Sensitivity 26/28093% (84-100%) 27.5/28098% (93-100%)
Specificity 1.5/3050% (0-100%) 1/3033% (0-86%)
Accuracy 27.5/31089% (77-100%) 28.5/31092% (82-100%)
PPV 26/27.5095% (86-100%) 27.5/29.5093% (84-100%)
NPV 1.5/3.5042% (0-93%) 1/1.5075% (6-100%)
Table 2 T-staging results of MRI and FDG-PET/CT (average values
from two readers). Resulting T-staging accuracy is 63% (95% CI, 46–
80%) for MRI and 56% (39–73%) for FDG-PET/CT
T-staging Histology
T0 T1 T2 T3 T4
total 3 10 14 2 2
MRI T0 1.5 2 0 0 0
T1 1.5 6 3 0 0.5
T2 0 1 10.5 1 0.5
T3 0 1 0 1 0.5
T4 0 0 0.5 0 0.5
PET/CT T0 1 0.5 0 0 0
T1 2 7.5 3 0 0.5
T2 0 2 7.5 0.5 0.5
T3 0 0 2.5 1 0.5
T4 0 0 1 0.5 0.5
Table 3 N-staging results for MRI and FDG-PET/CT (average values
from two readers). Resulting N-staging accuracy is 66% (95% CI: 49–
83%) for MRI and 71% (55–87%) for FDG-PET/CT
N-staging Histology
N0 N1 N2 N3
total 20 5 6 0
MRI N0 16.5 3 3 0
N1 2 1.5 0.5 0
N2 1 0.5 2.5 0
N3 0.5 0 0 0
PET/CT N0 17.5 2 3 0
N1 2.5 2.5 1 0
N2 0 0.5 2 0
N3 0 0 0 0
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preoperative assessment of NSCLC in comparison with
PET/CT with histopathology and cytology as the reference
standards.
With respect to primary tumour detection, MRI and PET/
CT both provided excellent results with sensitivity, accuracy
and PPV of more than 89% for both techniques. The values
obtained for sensitivity and accuracy are similar to previously
reported results [9–12] which are 70–100% sensitivity and
72–100% accuracy for MRI, and 76–100% sensitivity and
74–100% accuracy for PET/CT, respectively. The values for
specificity and NPV derived from the current study should be
interpreted with caution because of the small sample size with
only three non-malignant lesions. Specificity values for pri-
mary tumour detection reported in the literature are 96–97%
for MRI and 79–82% for PET/CT [9–12].
Accuracy of T-staging is found to be slightly higher for
MRI (63%) compared with 56% for PET/CT. However, this
difference is far from being statistically significant (P00.6).
To the best of our knowledge, there are no published data on
T-staging accuracy of MRI with diffusion weighting in
NSCLC patients. The observed accuracy of 56% for PET/
CT is in good accordance with the results from a recently
published retrospective study [28]. In general, published
values for T-staging accuracy of PET/CT cover a wide range
from 88% [3] down to only 39% in a study focused on stage
IIIA disease [29]. In our study, most T-staging errors oc-
curred with both techniques by mixing stages T1 and T2,
which is of limited clinical relevance.
N-staging is a key issue in preoperative work-up of
NSCLC patients. Until submission of this work, four studies
had compared the value of diffusion-weighted MRI and
PET/CT for lymph node assessment in NSCLC patients
[11–14]. The published results from these studies were 67–
91% sensitivity, 87–99% specificity and 80–98% accuracy
for MRI, compared with 48–98% sensitivity, 89–97% spec-
ificity and 80–97% accuracy for PET/CT. The specificity
and accuracy values observed in our study are in very good
accordance with these results. However, sensitivity values
calculated from our data are lower than the reported values
for both techniques. It is well known that FDG-PET is
considerably limited in detecting small lymph node metas-
tases. A study that evaluated size dependence of PET/CT in
N-staging of NSCLC patients reported a sensitivity of only
32% in lymph nodes <10 mm compared with 85% in lymph
nodes >10 mm leading to a moderate sensitivity of 54%
overall [30]. Another recently published study on PET/CT
in early stage NSCLC also revealed low sensitivity for
lymph node involvement of 44% [31]. In our study, approx-
imately half of the false-negative lymph nodes were metas-
tases smaller than 10 mm. In our opinion, this explains
sufficiently the sensitivity results provided by PET/CT.
The question of spatial resolution limitations in NSCLC
lymph node staging with diffusion-weighted MRI is dis-
cussed controversially in literature. The authors of one recent-
ly published study [11] claim that MRI may be superior to
PET/CT in detecting small lymph node metastases, thus
resulting in higher overall sensitivity and accuracy for MRI.
Others [12, 13] see no relevant advantage of MRI in this
respect, but describe higher accuracy and PPV of MRI com-
pared with PET/CT owing to fewer false-positive findings.
Sensitivity and PPV for metastatic lymph node involvement
cannot be assessed with sufficient accuracy by our study
because of the small sample size. Differences in accuracy,
however, that are seen in our data between diffusion-weighted
MRI and PET/CT regarding assessment of lymph node
Table 4 Group-wise assessment of metastatic lymph node involvement by MRI and FDG-PET/CT (average values from two readers). Values in
parentheses indicate 95% confidence intervals
Lymph node assessment N1 nodes N2 nodes Total (N1-N3)
MRI PET/CT MRI PET/CT MRI PET/CT
Sensitivity [%] 45 (14-76) 55 (24-88) 42 (2-81) 33 (0-71) 44 (19-68) 47 (22-71)
Specificity [%] 86 (71-100) 88 (74-100) 92 (81-100) 98 (93-100) 93 (87-99) 96 (92-100)
Accuracy [%] 73 (57-88) 78 (63-92) 82 (68-96) 86 (73-98) 85 (72-97) 88 (76-99)
PPV [%] 65 (31-99) 66 (34-99) 58 (12-100) 83 (37-100) 61 (34-88) 71 (44-99)
NPV [%] 77 (59-94) 82 (66-97) 87 (74-100) 86 (73-99) 89 (82-96) 90 (83-96)
Table 5 UICC staging results for MRI and FDG-PET/CT (average
values from two readers). Resulting UICC staging accuracy is 66%
(95% CI, 49–83%) for MRI and 74% (59–89%) for FDG-PET/CT
UICC-Staging Histology
0 I-II IIIA IIIB-IV
total 3 17 6 5
MRI 0 1.5 2 0 0
I-II 1.5 12.5 3 1
IIIA 0 1 3 0.5
IIIB-IV 0 1.5 0 3.5
PET/CT 0 1 0.5 0 0
I-II 2 14.5 2.5 0.5
IIIA 0 1.5 3.5 0.5
IIIB-IV 0 0.5 0 4
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groups and N-staging are far from being statistically signifi-
cant (P00.42 and 0.65). Thus, even considering the fact that
the sample size included by Usuda et al. [11] is twice as high
as in our study, we are not able to reproduce the very positive
results for MRI given by this previous study.
Accuracy of UICC staging in NSCLC by means of
diffusion-weighted MRI has to our knowledge only been
investigated by one earlier study [11]. The reported values of
71% for DWI and 65% for PET/CT are in good accordance
with the results from our study (66% for DWI and 74% for
PET/CT). The slight difference that is observed in favour of
PET/CT is not reflected by the individual T- and N-staging
results and is statistically not significant. The level of confi-
dence (P00.4) is almost equal to the number given by Usuda
et al. (P00.44) [11].
The method of diffusion-weighted whole-body MRI that
has been evaluated in this study is from a technical perspec-
tive comparable to the methods that have been used by
Fig. 1 Sample case of a 50-year-old man with primary tuberculosis.
Upper row: FDG-PET source images in inverted grey scale (a, c), and
combined PET/CT images after fusion of PET data on CT images in
lung (b) and soft tissue window (d). Lower row: High b-value
diffusion-weighted MRI source images in inverted grey scale (e, g),
and combined images from high b-value diffusion-weighted and T1-
weighted MRI data (f, h). This case was rated false positive for
malignancy (T1a N1, UICC IIA) by both PET/CT readers due to high
FDG-uptake in both the primary lesion (a, b) and in a right hilar lymph
node (c, d). On MRI, one of the readers considered the primary lesion
to be malignant (T1) due to a small area of restricted diffusion within
the primary lesion (arrows in e, f), whereas the second reader correctly
identified the lesion as benign. Both MRI readers correctly described
no suspicious lymphadenopathy (g, h)
Fig. 2 Sample case of a 55-year-old man with pT2b pN1, UICC IIB
squamous cell carcinoma. Upper row: FDG-PET source image (a), orig-
inal CT images in soft tissue (c) and lung window (d), and combined PET/
CT image (b). Lower row: High b-value diffusion-weighted source image
(e), combined image from high b-value DWI and T1-weighted MRI (f),
T2-weighted STIR image (g), and ADC-map (h). This case was rated false
positive for N2-disease by one of the MRI readers due to increased signal
intensity in a right paratracheal lymph node (arrows) on both T2-weighted
STIR and high b-value DWI. Increased ADCmean (1.9×10
-3 mm2/s mea-
sured with a 2D ROI in h) was interpreted by this reader as necrotic
changes. PET/CT showed no increased FDG-uptake in this location (a/b).
T-stage, however, was overestimated in the same patient by both PET/CT
readers (T4 and T3) due to inflammatory changes in the surrounding lung
parenchyma, but correctly assessed by both MRI readers
2864 Eur Radiol (2012) 22:2859–2867
previous authors. We chose a very simple approach for our
protocol including two b values, free-breathing acquisition,
STIR–fat suppression and a moderate number of averages to
facilitate efficient whole-body coverage. Potential technical
improvements as applied by other authors would be the use
of more or higher b values, more elaborate methods of fat
saturation such as spectral pre-saturation inversion recovery
(SPAIR), and a higher number of averages. With reference
to former studies, as cited above, we would expect most of
these modifications to have only minor effects on overall
staging accuracy. Artefacts from breathing motion and car-
diovascular pulsations, however, were significantly more
important in all MRI sequences applied in our study com-
pared with PET/CT and represent a major issue in this
context. The use of breath-holding, respiratory gating and
ECG gating techniques may improve delineation of anatom-
ical structures particularly in the central part of the chest and
thus may further increase sensitivity for small central pul-
monary lesions and mediastinal lymph nodes.
This study has several limitations. First to mention is the
small patient number that particularly compromises the cal-
culation accuracy of specificity and NPV for primary tu-
mour detection and sensitivity and PPV for detection of
lymph node metastases. Second, no valuable data on N3
lymph nodes could be obtained, as only patients with a
potentially resectable stage of disease were included in the
study. For the same reason, M-stage could not be assessed
reliably as only two patients with solitary brain or lung
metastases and curative intention for surgery were included.
Thus, also the clinically important question of differentiat-
ing between UICC stages IA–IIIA and stages IIIB–IV has
not been addressed. Another limitation of the study design is
the delay between PET/CT and surgery being systematically
longer than between MRI and surgery. This might be inter-
preted as a bias in favour of MRI. However, we also ob-
served two cases where the interpretation of MRI was
impaired considerably by post-stenotic pneumonia or atel-
ectasis that was not present at the time of the PET/CT
examination. A systematic disadvantage for MRI that has
to be discussed is reading expertise: radiologists and nuclear
medicine physicians who acted as readers in this study had
comparable expertise in their fields. However, compared
with PET/CT, reading of DWIBS images is not yet stand-
ardised well and individual experience of readers with this
new technique is still limited even for otherwise experienced
radiologists. This is expressed by lower observer agreement
for MRI compared with PET/CT in our study. Finally, the
study outcome for both imaging techniques is limited by the
fact that all staging results are based on the impression of a
single board-certified radiologist or nuclear medicine phy-
sician. However, this reflects a quite common situation in
clinical practise. It can reasonably be assumed that addition-
al consensus readings in cases of discrepancy would likely
have improved staging accuracies for both techniques.
In conclusion, this study has shown, in agreement with
previously published studies, that whole-body MRI with
DWIBS is a powerful method for staging of NSCLC and
provides results comparable to the reference standard PET/
CT. Thus, whole-body MRI with DWIBS may qualify as first
line technique for staging of NSCLC when PET/CT is not
available. However, as opposed to other authors, we are not
yet convinced that there is clear evidence of a superiority of
DWI with respect to lymph node assessment. We agree that
the method of diffusion-weighted MRI has two intrinsic
Fig. 3 Schematic overview of tumour detection and staging accuracies for MRI and PET/CT. The error bars represent 95% confidence intervals
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technical advantages over FDG-PET, which are spatial reso-
lution and soft tissue contrast. However, this potential has not
been exploited to its full extent by today’s routinely available
applications. There is certainly a need for further technical
improvement of both diffusion-weighted and conventional
MRI sequences for optimised morphological and functional
assessment of pulmonary and mediastinal structures.
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